Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal.

Numerous animal studies suggest that acute and chronic exposure to opioids can be associated with the development of hyperalgesia, i.e. an increased sensitivity to noxious stimuli.